Refractory Multiple Myeloma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：300頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Refractory Multiple Myeloma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Refractory Multiple Myeloma - Pipeline Review, H1 2014’, provides an overview of the Refractory Multiple Myeloma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Refractory Multiple Myeloma - Pipeline Review, H1 2014’, provides an overview of the Refractory Multiple Myeloma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Refractory Multiple Myeloma Overview 8
Therapeutics Development 9
Pipeline Products for Refractory Multiple Myeloma - Overview 9
Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis 10
Refractory Multiple Myeloma - Therapeutics under Development by Companies 11
Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 15
Refractory Multiple Myeloma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Refractory Multiple Myeloma - Products under Development by Companies 18
Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes 20
Refractory Multiple Myeloma - Companies Involved in Therapeutics Development 21
Bristol-Myers Squibb Company 21
Johnson & Johnson 22
Kyowa Hakko Kirin Co., Ltd. 23
Sanofi 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Genentech, Inc. 27
Piramal Enterprises Limited 28
Prolexys Pharmaceuticals, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Astellas Pharma Inc. 32
Pfizer Inc. 33
Exelixis, Inc. 34
Celgene Corporation 35
Onyx Pharmaceuticals, Inc. 36
Incyte Corporation 37
Oncolytics Biotech Inc. 38
Pharmacyclics, Inc. 39
Array BioPharma Inc. 40
MorphoSys AG 41
Senesco Technologies, Inc. 42
Threshold Pharmaceuticals, Inc. 43
Synta Pharmaceuticals Corp. 44
Acceleron Pharma, Inc. 45
Altor BioScience Corporation 46
Stemline Therapeutics, Inc. 47
Acetylon Pharmaceuticals, Inc. 48
Pharma Mar, S.A. 49
Janssen Biotech, Inc. 50
AbbVie Inc. 51
Oncopeptides AB 52
Senhwa Biosciences 53
Refractory Multiple Myeloma - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 60
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
ixazomib citrate - Drug Profile 68
panobinostat - Drug Profile 70
carfilzomib - Drug Profile 76
elotuzumab - Drug Profile 79
plitidepsin - Drug Profile 81
bendamustine - Drug Profile 83
ibrutinib - Drug Profile 85
ruxolitinib phosphate - Drug Profile 89
ARRY-520 - Drug Profile 93
ALT-801 - Drug Profile 95
pomalidomide - Drug Profile 97
chloroquine + [bortezomib] + [cyclophosphamide] - Drug Profile 100
Melflufen - Drug Profile 101
Circularly Permuted TRAIL - Drug Profile 103
alisertib - Drug Profile 104
daratumumab - Drug Profile 107
PRLX-93936 - Drug Profile 109
carfilzomib - Drug Profile 111
cabozantinib (s)-malate - Drug Profile 114
SNS-01T - Drug Profile 117
SL-401 - Drug Profile 119
TH-302 - Drug Profile 121
P-276 - Drug Profile 128
MOR-202 - Drug Profile 130
KW-2478 - Drug Profile 132
palbociclib - Drug Profile 133
luminespib - Drug Profile 136
plerixafor - Drug Profile 139
ricolinostat - Drug Profile 141
LY-2812176 - Drug Profile 143
tabalumab - Drug Profile 145
BMS-833923 - Drug Profile 147
dalantercept - Drug Profile 149
SAR-650984 - Drug Profile 151
dasatinib - Drug Profile 153
ganetespib - Drug Profile 156
pelareorep - Drug Profile 160
ulocuplumab - Drug Profile 164
tipifarnib - Drug Profile 165
veliparib - Drug Profile 167
silmitasertib - Drug Profile 169
pomalidomide - Drug Profile 171
afuresertib - Drug Profile 174
MV-NIS Vaccine - Drug Profile 176
ABT-199 - Drug Profile 178
RG-7598 - Drug Profile 181
LGH-447 - Drug Profile 182
hydroxychloroquine + sirolimus - Drug Profile 183
Refractory Multiple Myeloma - Recent Pipeline Updates 184
Refractory Multiple Myeloma - Dormant Projects 282
Refractory Multiple Myeloma - Discontinued Products 283
Refractory Multiple Myeloma - Product Development Milestones 284
Featured News & Press Releases 284
Appendix 295
Methodology 295
Coverage 295
Secondary Research 295
Primary Research 295
Expert Panel Validation 295
Contact Us 296
Disclaimer 296
List of Tables
Number of Products under Development for Refractory Multiple Myeloma, H1 2014 13
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2014 25
Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2014 26
Refractory Multiple Myeloma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 27
Refractory Multiple Myeloma - Pipeline by Sanofi, H1 2014 28
Refractory Multiple Myeloma - Pipeline by Eli Lilly and Company, H1 2014 29
Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2014 30
Refractory Multiple Myeloma - Pipeline by Genentech, Inc., H1 2014 31
Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited , H1 2014 32
Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2014 33
Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 34
Refractory Multiple Myeloma - Pipeline by Novartis AG, H1 2014 35
Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2014 36
Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H1 2014 37
Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2014 38
Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H1 2014 39
Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 40
Refractory Multiple Myeloma - Pipeline by Incyte Corporation, H1 2014 41
Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2014 42
Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2014 43
Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2014 44
Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H1 2014 45
Refractory Multiple Myeloma - Pipeline by Senesco Technologies, Inc., H1 2014 46
Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 47
Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2014 48
Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2014 49
Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2014 50
Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2014 51
Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014 52
Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2014 53
Refractory Multiple Myeloma - Pipeline by Janssen Biotech, Inc., H1 2014 54
Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H1 2014 55
Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2014 56
Refractory Multiple Myeloma - Pipeline by Senhwa Biosciences, H1 2014 57
Assessment by Monotherapy Products, H1 2014 58
Assessment by Combination Products, H1 2014 59
Number of Products by Stage and Target, H1 2014 62
Number of Products by Stage and Mechanism of Action, H1 2014 66
Number of Products by Stage and Route of Administration, H1 2014 69
Number of Products by Stage and Molecule Type, H1 2014 71
Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2014 188
Refractory Multiple Myeloma - Dormant Projects, H1 2014 286
Refractory Multiple Myeloma - Discontinued Products, H1 2014 287
List of Figures
Number of Products under Development for Refractory Multiple Myeloma, H1 2014 13
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 21
Assessment by Monotherapy Products, H1 2014 58
Assessment by Combination Products, H1 2014 59
Number of Products by Top 10 Target, H1 2014 60
Number of Products by Stage and Top 10 Target, H1 2014 61
Number of Products by Top 10 Mechanism of Action, H1 2014 64
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 65
Number of Products by Top 10 Route of Administration, H1 2014 68
Number of Products by Stage and Top 10 Route of Administration, H1 2014 69
Number of Products by Top 10 Molecule Type, H1 2014 70
Number of Products by Stage and Top 10 Molecule Type, H1 2014 71
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Refractory Multiple Myeloma Overview 8
Therapeutics Development 9
Pipeline Products for Refractory Multiple Myeloma - Overview 9
Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis 10
Refractory Multiple Myeloma - Therapeutics under Development by Companies 11
Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 15
Refractory Multiple Myeloma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Refractory Multiple Myeloma - Products under Development by Companies 18
Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes 20
Refractory Multiple Myeloma - Companies Involved in Therapeutics Development 21
Bristol-Myers Squibb Company 21
Johnson & Johnson 22
Kyowa Hakko Kirin Co., Ltd. 23
Sanofi 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Genentech, Inc. 27
Piramal Enterprises Limited 28
Prolexys Pharmaceuticals, Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
Astellas Pharma Inc. 32
Pfizer Inc. 33
Exelixis, Inc. 34
Celgene Corporation 35
Onyx Pharmaceuticals, Inc. 36
Incyte Corporation 37
Oncolytics Biotech Inc. 38
Pharmacyclics, Inc. 39
Array BioPharma Inc. 40
MorphoSys AG 41
Senesco Technologies, Inc. 42
Threshold Pharmaceuticals, Inc. 43
Synta Pharmaceuticals Corp. 44
Acceleron Pharma, Inc. 45
Altor BioScience Corporation 46
Stemline Therapeutics, Inc. 47
Acetylon Pharmaceuticals, Inc. 48
Pharma Mar, S.A. 49
Janssen Biotech, Inc. 50
AbbVie Inc. 51
Oncopeptides AB 52
Senhwa Biosciences 53
Refractory Multiple Myeloma - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Target 56
Assessment by Mechanism of Action 60
Assessment by Route of Administration 64
Assessment by Molecule Type 66
Drug Profiles 68
ixazomib citrate - Drug Profile 68
panobinostat - Drug Profile 70
carfilzomib - Drug Profile 76
elotuzumab - Drug Profile 79
plitidepsin - Drug Profile 81
bendamustine - Drug Profile 83
ibrutinib - Drug Profile 85
ruxolitinib phosphate - Drug Profile 89
ARRY-520 - Drug Profile 93
ALT-801 - Drug Profile 95
pomalidomide - Drug Profile 97
chloroquine + [bortezomib] + [cyclophosphamide] - Drug Profile 100
Melflufen - Drug Profile 101
Circularly Permuted TRAIL - Drug Profile 103
alisertib - Drug Profile 104
daratumumab - Drug Profile 107
PRLX-93936 - Drug Profile 109
carfilzomib - Drug Profile 111
cabozantinib (s)-malate - Drug Profile 114
SNS-01T - Drug Profile 117
SL-401 - Drug Profile 119
TH-302 - Drug Profile 121
P-276 - Drug Profile 128
MOR-202 - Drug Profile 130
KW-2478 - Drug Profile 132
palbociclib - Drug Profile 133
luminespib - Drug Profile 136
plerixafor - Drug Profile 139
ricolinostat - Drug Profile 141
LY-2812176 - Drug Profile 143
tabalumab - Drug Profile 145
BMS-833923 - Drug Profile 147
dalantercept - Drug Profile 149
SAR-650984 - Drug Profile 151
dasatinib - Drug Profile 153
ganetespib - Drug Profile 156
pelareorep - Drug Profile 160
ulocuplumab - Drug Profile 164
tipifarnib - Drug Profile 165
veliparib - Drug Profile 167
silmitasertib - Drug Profile 169
pomalidomide - Drug Profile 171
afuresertib - Drug Profile 174
MV-NIS Vaccine - Drug Profile 176
ABT-199 - Drug Profile 178
RG-7598 - Drug Profile 181
LGH-447 - Drug Profile 182
hydroxychloroquine + sirolimus - Drug Profile 183
Refractory Multiple Myeloma - Recent Pipeline Updates 184
Refractory Multiple Myeloma - Dormant Projects 282
Refractory Multiple Myeloma - Discontinued Products 283
Refractory Multiple Myeloma - Product Development Milestones 284
Featured News & Press Releases 284
Appendix 295
Methodology 295
Coverage 295
Secondary Research 295
Primary Research 295
Expert Panel Validation 295
Contact Us 296
Disclaimer 296
List of Tables
Number of Products under Development for Refractory Multiple Myeloma, H1 2014 13
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2014 24
Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2014 25
Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2014 26
Refractory Multiple Myeloma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 27
Refractory Multiple Myeloma - Pipeline by Sanofi, H1 2014 28
Refractory Multiple Myeloma - Pipeline by Eli Lilly and Company, H1 2014 29
Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2014 30
Refractory Multiple Myeloma - Pipeline by Genentech, Inc., H1 2014 31
Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited , H1 2014 32
Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2014 33
Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 34
Refractory Multiple Myeloma - Pipeline by Novartis AG, H1 2014 35
Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2014 36
Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H1 2014 37
Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2014 38
Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H1 2014 39
Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 40
Refractory Multiple Myeloma - Pipeline by Incyte Corporation, H1 2014 41
Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2014 42
Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2014 43
Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2014 44
Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H1 2014 45
Refractory Multiple Myeloma - Pipeline by Senesco Technologies, Inc., H1 2014 46
Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 47
Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2014 48
Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2014 49
Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2014 50
Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2014 51
Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014 52
Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2014 53
Refractory Multiple Myeloma - Pipeline by Janssen Biotech, Inc., H1 2014 54
Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H1 2014 55
Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2014 56
Refractory Multiple Myeloma - Pipeline by Senhwa Biosciences, H1 2014 57
Assessment by Monotherapy Products, H1 2014 58
Assessment by Combination Products, H1 2014 59
Number of Products by Stage and Target, H1 2014 62
Number of Products by Stage and Mechanism of Action, H1 2014 66
Number of Products by Stage and Route of Administration, H1 2014 69
Number of Products by Stage and Molecule Type, H1 2014 71
Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2014 188
Refractory Multiple Myeloma - Dormant Projects, H1 2014 286
Refractory Multiple Myeloma - Discontinued Products, H1 2014 287
List of Figures
Number of Products under Development for Refractory Multiple Myeloma, H1 2014 13
Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 21
Assessment by Monotherapy Products, H1 2014 58
Assessment by Combination Products, H1 2014 59
Number of Products by Top 10 Target, H1 2014 60
Number of Products by Stage and Top 10 Target, H1 2014 61
Number of Products by Top 10 Mechanism of Action, H1 2014 64
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 65
Number of Products by Top 10 Route of Administration, H1 2014 68
Number of Products by Stage and Top 10 Route of Administration, H1 2014 69
Number of Products by Top 10 Molecule Type, H1 2014 70
Number of Products by Stage and Top 10 Molecule Type, H1 2014 71
